Eli Lilly (LLY) sued over vision-loss claims tied to weight-loss drugs

Patients who suddenly lost sight after taking Zepbound and Mounjaro are suing Eli Lilly, claiming the drugmaker failed to warn them of a rare eye condition called NAION. Novo Nordisk faces parallel claims over Ozempic and Wegovy. Both companies deny a proven link, and US regulators are still reviewing whether one exists. It hits Lilly's biggest growth engine, its weight-loss franchise.